Vir Biotechnology, Inc. (VIR) Spending and interest coverage
- R&D / revenue · 12 months: Value 159.62%; Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value 15.51%; Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | 159.62% | Research and development expense / revenue. Period ending 2026-06-30. $484.02M ÷ $303.23M × 100 ≈ 159.62% |
| Stock-based compensation / revenue · 12 months | 15.51% | Share-based compensation / revenue. Period ending 2026-06-30. $47.04M ÷ $303.23M × 100 ≈ 15.51% |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 484.02M USD | Research and Development Expense |
| Revenue | 303.23M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | 47.04M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -280.19M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $484.02M | $303.23M | $47.04M | $-280.19M | (m) | 159.62% | 15.51% | (m) | (m) |
| 2026-03-31 | $446.24M | $65.50M | $47.10M | $-472.07M | (m) | 681.34% | 71.91% | (m) | (m) |
| 2025-12-31 | $455.97M | $68.56M | $49.07M | $-479.33M | (m) | 665.10% | 71.58% | (m) | (m) |
| 2025-09-30 | $473.70M | $16.86M | $53.71M | $-548.56M | (m) | 2809.61% | 318.55% | (m) | (m) |
| 2025-06-30 | $517.41M | $19.00M | $59.05M | $-606.42M | (m) | 2723.24% | 310.78% | (m) | (m) |
| 2025-03-31 | $525.02M | $20.86M | $68.76M | $-646.63M | (m) | 2516.75% | 329.61% | (m) | (m) |
| 2024-12-31 | $506.50M | $74.20M | $78.46M | $-587.16M | (m) | 682.57% | 105.73% | (m) | (m) |
| 2024-09-30 | $519.33M | $78.62M | $90.89M | $-609.03M | (m) | 660.58% | 115.61% | (m) | (m) |
| 2024-06-30 | $469.18M | $78.88M | $101.14M | $-564.46M | (m) | 594.83% | 128.22% | (m) | (m) |
| 2024-03-31 | $532.15M | $79.60M | $109.59M | $-621.01M | (m) | 668.54% | 137.68% | (m) | (m) |
| 2023-12-31 | $589.67M | $86.18M | $111.32M | $-684.30M | (m) | 684.23% | 129.17% | (m) | (m) |
| 2023-09-30 | $632.93M | $118.80M | $107.91M | $-695.79M | (m) | 532.76% | 90.83% | (m) | (m) |
| 2023-06-30 | $598.84M | $490.72M | $105.78M | $-314.10M | (m) | 122.03% | 21.56% | (m) | (m) |
| 2023-03-31 | $542.06M | $446.30M | $102.26M | $-324.13M | (m) | 121.46% | 22.91% | (m) | (m) |
| 2022-12-31 | $474.65M | $1.62B | $102.08M | $833.07M | (m) | 29.38% | 6.32% | (m) | (m) |
| 2022-09-30 | $447.82M | $2.38B | $101.59M | $1.56B | (m) | 18.82% | 4.27% | (m) | (m) |
| 2022-06-30 | $432.32M | $2.11B | $99.72M | $1.31B | (m) | 20.51% | 4.73% | (m) | (m) |
| 2022-03-31 | $403.36M | $2.33B | $93.62M | $1.59B | (m) | 17.34% | 4.02% | (m) | (m) |
| 2021-12-31 | $448.01M | $1.10B | $83.78M | $420.75M | (m) | 40.90% | 7.65% | (m) | (m) |
| 2021-09-30 | $406.76M | $284.40M | $69.71M | $-259.40M | (m) | 143.02% | 24.51% | (m) | (m) |
| 2021-06-30 | $378.77M | $182.71M | $55.35M | $-293.63M | (m) | 207.30% | 30.29% | (m) | (m) |
| 2021-03-31 | $372.30M | $72.63M | $40.10M | $-383.70M | (m) | 512.63% | 55.22% | (m) | (m) |
| 2020-12-31 | $302.41M | $76.37M | $27.60M | $-296.98M | (m) | 395.99% | 36.14% | (m) | (m) |
| 2020-09-30 | $268.25M | $75.61M | $19.98M | $-252.34M | (m) | 354.76% | 26.42% | (m) | (m) |
| 2020-06-30 | $237.43M | $75.09M | $13.58M | $-212.40M | (m) | 316.19% | 18.09% | (m) | (m) |
| 2020-03-31 | $187.58M | $10.15M | $9.23M | $-219.12M | (m) | 1848.43% | 90.98% | (m) | (m) |
| 2019-12-31 | $148.47M | $8.09M | $8.72M | $-177.98M | (m) | 1835.03% | 107.76% | (m) | (m) |
| 2019-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-06-30 | (m) | $11.72M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-03-31 | (m) | $11.90M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-12-31 | $100.23M | $10.67M | $5.05M | $-118.69M | (m) | 939.53% | 47.37% | (m) | (m) |
| 2018-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-12-31 | $62.51M | $2.71M | $4.78M | $-81.50M | (m) | 2308.42% | 176.59% | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |